In this article:
Protocol development in integrative medicine is not typically a simple process. Individuals require individualized care, and what works for one patient may not work for another.
As a result, the Fullscript Integrative Medical Advisory team advises using an evidence-informed approach to protocol development. To simplify this process for practitioners, we have assembled a sampling of evidence-based standardized protocols that practitioners can use as a foundation when developing individualized protocols.
To establish these protocols, we first developed a Rating Scale that could be used to discern the rigor of evidence supporting a specific nutrient’s therapeutic effect.
The following protocols were developed using only A through C-quality evidence. These are categorized as follows:
A Systematic review or meta-analysis
B Randomized Double Blind Placebo Controlled (RDBPC) 2+ studies and/or 1 study with 50 + subjects
C Randomized Double Blind Placebo Controlled (RDBPC) 1 study
Please refer to the complete Rating Scale for further information.
The ingredients included in these protocols are based on a review of existing clinical research, with a priority placed on systematic reviews and meta-analyses, classified as A in the Rating Scale.
These protocols are intended to form a foundation for developing individualized treatment plans. Clinician discretion is highly advised, as ingredients can vary in safety and effectiveness, depending on the needs of the individual patient.
Ingredient-Based Protocol: Osteoarthritis
1.5 to 2 g, per day, minimum 12 weeks1
- Individual RDBPC studies consistently demonstrate reduction in pain and global symptoms of OA2
- However, reviews and meta-analyses do not confirm this finding3
Combination with chondroitin may increase overall effectiveness4
Search for Glucosamine in the Fullscript catalog.
1200 mg, one to two times per day, minimum 30 days5
- Demonstrated effectiveness at reducing symptoms of osteoarthritis6
- Multiple RDBPC studies demonstrated comparable pain reduction to OTC pharmaceuticals like naproxen and nabumetone5,7
Search for SAMe in the Fullscript catalog.
Turmeric (Curcuma longa)
500 mg MERIVA, two to four times per day, minimum 30 days8
- In small clinical trials (< 100 subjects), demonstrated effect in pain reduction, comparable to ibuprofen.9
- One recent review confirmed that both whole turmeric extract and curcumin demonstrated short-term reduction in pain10
Additional promising interventions with preliminary evidence demonstrating reduction in OA symptoms include:
- Green-lipped mussel extract
- Indian Frankincense (Boswellia serrata)
- Natural Eggshell Membrane
- Type II Collagen
Adding Protocols to your Fullscript Catalog
Create a Category
- Click the Catalog button
- Click the “Your Favorites” tab
- Click “Add Category” and add name
- Add products
Categories can be used for quick reference or for patient use when accessing the catalog (depending on catalog settings).
Create a Template
- Click the “Prescriptions” button
- Click “Manage your prescription templates”
- Click “Create a new template”
- Add a title, products, dosing, message, and attachments
- Click “Save Template”
Templates can be accessed and applied when creating a new prescription for your patients.
Write a Prescription
- Click the “New Prescription” button
- Click the “Templates” button in the right-hand menu column
- Click the “Apply” button beside the template you wish to apply
- Modify as needed
- Click the “Send to Patient” button!
Visit the Fullscript Integrative Clinical Education Hub for a full review of the literature used to develop this protocol.
We’d be happy to help you create a protocol containing these ingredients in your Fullscript catalog! Contact our Customer Success team for assistance.
1 (B) - https://www.ncbi.nlm.nih.gov/pubmed/12374520
2 (A) - https://www.ncbi.nlm.nih.gov/pubmed/12860572
3 (A) - https://www.ncbi.nlm.nih.gov/pubmed/20847017
4 (A) - https://www.ncbi.nlm.nih.gov/pubmed/10732937
5 (B) - https://www.ncbi.nlm.nih.gov/pubmed/3318442
6 (B) - https://www.ncbi.nlm.nih.gov/pubmed/15102339
7 (B) - https://www.ncbi.nlm.nih.gov/pubmed/20110025
8 (B) - https://www.ncbi.nlm.nih.gov/pubmed/21194249
9 (B) - https://www.ncbi.nlm.nih.gov/pubmed/19678780
10 (C) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596124/